Cargando…
Bimekizumab: the new drug in the biologics armamentarium for psoriasis
Bimekizumab, a humanized monoclonal IgG1 antibody being currently evaluated for multiple immune-mediated diseases, is mentioned in the recent report by Clarivate, Drugs to Watch in 2021, as one of the drugs to be observed in 2021. Due to its novel mechanism of action (dual inhibition of IL-17A and I...
Autores principales: | Freitas, Egídio, Torres, Tiago |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195566/ https://www.ncbi.nlm.nih.gov/pubmed/34178093 http://dx.doi.org/10.7573/dic.2021-4-1 |
Ejemplares similares
-
Bimekizumab for plaque psoriasis
Publicado: (2022) -
Review of bimekizumab in the treatment of psoriasis
por: Koppu, Sindhuja, et al.
Publicado: (2022) -
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
por: Ruggiero, Angelo, et al.
Publicado: (2022) -
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives
por: Camiña-Conforto, Gemma, et al.
Publicado: (2023) -
A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)